Client News
AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
TVM Capital Life Science Announces €8 Million Investment in myo to Revolutionize Elderly Care via Innovative, Easy-to-Use App
Gedeon Richter becomes strategic investor of Formycon via equity investment
Affluent Medical closes €3.5 million bridge via capital increase from key shareholders
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
G.ST Antivirals reports positive Phase I trial results for 2-Deoxy-D-glucose against upper respiratory infections
AiCuris and the German Center for Infection Research (DZIF) sign Collaboration and License Option Agreement
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
